Medicinal Chemistry Journal of Medicinal Chemistry (ACS)

Branched acyl-lysine peptides turn SIRT2 substrates into slow-turnover inhibitors that work in cells

  • Peptides bearing methyl-branched or cyclopropyl-modified acyl groups on lysine inhibit SIRT2 potently, lingering on the enzyme with almost no turnover, as expected for slow substrates.
  • Crystal structures with NAD+ show a competent but unproductive enzyme state, and comparison with SIRT1 and SIRT3 reveals isoform-specific acyl-chain paths behind selectivity.
  • Optimized peptides engage SIRT2 in cells and raise alpha-tubulin acetylation.
Points Based on the abstract

Is this really inhibition or just a substrate the enzyme chews through slowly? The cell data suggest the former, but I'd want the thioacylation intermediate shown directly and a deacylase-dead SIRT2 control. Peptides still carry permeability and stability baggage, so the next step is a macrocyclic or peptidomimetic version, benchmarked against SirReal-type and thiomyristoyl inhibitors.